Efficacy News and Research

RSS

Civitas reports positive results from CVT-301 Phase 2b trial for treatment of Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing and commercializing transformative therapeutics using its proprietary ARCUSTM technology, today announced positive results from a Phase 2b clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa).

29 Apr 2014

Positive results from pivotal clinical trial of Trophos’ olesoxime in SMA patients to be presented at AAN 2014

Trophos and AFM-Telethon today announce that data from the pivotal clinical trial of Trophos’ lead product candidate olesoxime in spinal muscular atrophy (SMA) will be presented during the 66th American Academy of Neurology annual meeting to be held in Philadelphia, PA, USA, from April 26 to May 3 2014.

29 Apr 2014

Highland subsidiary begins enrolment in Phase III study of HLD-200 in pediatric ADHD patients

Highland Therapeutics Inc., an emerging pharmaceutical company, today announced that its wholly owned subsidiary has begun enrolment in a Phase III study of HLD-200, the Company's novel formulation of methylphenidate, in pediatric patients with Attention-Deficit Hyperactivity Disorder ("ADHD").

28 Apr 2014

Forest Laboratories enters into definitive agreement to acquire Furiex

Forest Laboratories, Inc. nd Furiex Pharmaceuticals, Inc. today announced that Forest has entered into a definitive agreement to acquire Furiex, a drug development collaboration company, for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in aggregate) in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

28 Apr 2014

European Commission approves VOKANAMET for treatment of adults with type 2 diabetes mellitus

Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved VOKANAMET® (a fixed-dose therapy combining canagliflozin and immediate release metformin hydrochloride in a single tablet) in the European Union, for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control.

26 Apr 2014

New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company's multiple sclerosis (MS) portfolio will be presented at the American Academy of Neurology's 66th Annual Meeting, taking place from April 26 – May 3, in Philadelphia, PA.

26 Apr 2014

Engineering breakthrough allows cancer researchers to create living tumors

Drexel's Wei Sun, PhD, Albert Soffa chair professor in the College of Engineering, has devised a method for 3D printing tumors that could soon be taking cancer research out of the petri dish.

26 Apr 2014

Promising new approach targets cancer protein to slow tumor growth

Sometimes a full-on assault isn't the best approach when dealing with a powerful enemy. A more effective approach, in the long run, may be to target the support system replenishing the supplies that keep your foe strong and ready for battle.

26 Apr 2014

Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Concert Pharmaceuticals, Inc. today announced 48-week results of its Phase 2 clinical trial of CTP-499 in patients with diabetic kidney disease. CTP-499, when used in addition to the standard of care, is being developed to delay the progression of these patients to end-stage renal failure, which requires dialysis or kidney transplantation.

26 Apr 2014

Variant of cell surface protein may help develop drugs for gastric cancer

A team of scientists led by a researcher from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has identified the cancer specific stem cell which causes gastric cancer. This discovery opens up the possibility of developing new drugs for the treatment of this disease and other types of cancers.

25 Apr 2014

NPF researchers to get access to Corrona’s psoriatic arthritis registry to improve patient outcomes

To improve treatment decisions and patient outcomes for psoriatic arthritis (PsA)—a chronic inflammatory arthritis that affects the joints and tendons—the National Psoriasis Foundation and Corrona, LLC are collaborating to give NPF-affiliated researchers access to Corrona’s psoriatic arthritis registry, which is the largest psoriatic arthritis registry in the world.

25 Apr 2014

TB Alliance advances first-ever TB drug regimen to global Phase 3 clinical trial

Based on positive results from earlier clinical studies, TB Alliance is advancing the first-ever drug regimen designed to treat both drug-sensitive and some forms of multi-drug resistant tuberculosis (TB) to a global Phase 3 clinical trial.

25 Apr 2014

Two sedative drugs effectively treat prolonged seizures in children

The sedative drugs diazepam (Valium) and lorazepam (Ativan) are equally effective in treating the prolonged seizures known as status epilepticus in children, according to a randomized, controlled study by a multi-institution team of researchers with the Pediatric Emergency Care Applied Research Network, including an expert from the Perelman School of Medicine at the University of Pennsylvania.

25 Apr 2014

Study offers evidence supporting use of autologous stem cell-based treatment for stroke

People who have had a stroke, often suffer motor deficits with little potential to restore neurological function.

25 Apr 2014

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Biogen Idec Inc. today reported first quarter 2014 results, including revenue of $2.1 billion, a 51% increase compared to the first quarter of 2013.

23 Apr 2014

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its pivotal trial of Captisol-enabled (propylene glycol-free) Melphalan met its primary end points.

23 Apr 2014

Efficacy News and Research

Civitas reports positive results from CVT-301 Phase 2b trial for treatment of Parkinson's disease

Positive results from pivotal clinical trial of Trophos’ olesoxime in SMA patients to be presented at AAN 2014

Highland subsidiary begins enrolment in Phase III study of HLD-200 in pediatric ADHD patients

Forest Laboratories enters into definitive agreement to acquire Furiex

European Commission approves VOKANAMET for treatment of adults with type 2 diabetes mellitus

New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

Engineering breakthrough allows cancer researchers to create living tumors

Promising new approach targets cancer protein to slow tumor growth

Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Variant of cell surface protein may help develop drugs for gastric cancer

NPF researchers to get access to Corrona’s psoriatic arthritis registry to improve patient outcomes

TB Alliance advances first-ever TB drug regimen to global Phase 3 clinical trial

Two sedative drugs effectively treat prolonged seizures in children

Study offers evidence supporting use of autologous stem cell-based treatment for stroke

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

HemoShear announces research collaboration with Medivir

Kala Pharmaceuticals completes $22.5 million Series B financing

Study suggests that variant of cell surface protein is ideal target to treat gastric cancer

Glaucoma drug may help reverse obesity-related vision loss in women

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News